Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains
Computationally designed protein nanoparticles have recently emerged as a promising platform for the development of new vaccines and biologics. For many applications, secretion of designed nanoparticles from eukaryotic cells would be advantageous, but in practice, they often secrete poorly. Here we...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 120; no. 11; p. e2214556120 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
14.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Computationally designed protein nanoparticles have recently emerged as a promising platform for the development of new vaccines and biologics. For many applications, secretion of designed nanoparticles from eukaryotic cells would be advantageous, but in practice, they often secrete poorly. Here we show that designed hydrophobic interfaces that drive nanoparticle assembly are often predicted to form cryptic transmembrane domains, suggesting that interaction with the membrane insertion machinery could limit efficient secretion. We develop a general computational protocol, the Degreaser, to design away cryptic transmembrane domains without sacrificing protein stability. The retroactive application of the Degreaser to previously designed nanoparticle components and nanoparticles considerably improves secretion, and modular integration of the Degreaser into design pipelines results in new nanoparticles that secrete as robustly as naturally occurring protein assemblies. Both the Degreaser protocol and the nanoparticles we describe may be broadly useful in biotechnological applications. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Bill & Melinda Gates Foundation (BMGF) Defense Threat Reduction Agency (DTRA) AC02-05CH11231; OPP1156262; OPP1115782; P30 GM124165; P50 AI150464; 1P01AI167966; HDTRA1-18-1-0001; NIH P41-GM103311; NIH R01-GM129325 USDOE Office of Science (SC), Basic Energy Sciences (BES) National Institutes of Health (NIH) 1J.Y.W. and A.K. contributed equally to this work. Edited by Daniel W. Kulp, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA; received August 26, 2022; accepted February 3, 2023 by Editorial Board Member William F. DeGrado |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.2214556120 |